Richard Silverman, MD
Critical Care Medicine · Waterbury, CTNPI 1679680110
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $500,560 of the $559,579 with a category attached, or 89.5%. AstraZeneca accounts for 91.7% of it on its own, with 45 other manufacturers making up the rest. Among critical care medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,406 payments — averaging $397.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$513K
- Verona Pharma, Inc.$21K
- Amgen$14K
- GSK$3K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $7K from 40 others
What the payments were for
- Consulting fees$7,4401%
- Speaking & faculty fees$500,56089%
- Travel & lodging$14,3943%
- Food & beverage$36,1446%
- Education$1,0410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$559,579 in reported general payments places this provider in the 95th percentile of 51 critical care medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 260 | $326,283 |
| Breo ElliptaFluticasone/Vilanterol | 273 | $179,216 |
| Dupixent PenDupilumab | 19 | $71,191 |
| Spiriva HandihalerTiotropium Bromide | 63 | $63,533 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 90 | $59,405 |
| SymbicortBudesonide/Formoterol Fumarate | 78 | $28,371 |
| Spiriva RespimatTiotropium Bromide | 23 | $25,152 |
| DuleraMometasone/Formoterol | 44 | $18,687 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 415 | $15,491 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $15,179 |
| Wixela InhubFluticasone Propion/Salmeterol | 73 | $12,994 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,672 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $11,451 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $10,614 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $9,321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,987 | $583,224656 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $513,225 | $41,04398 claims |
| Boehringer IngelheimSpiriva Respimat | $991 | $25,15223 claims |
| MerckDulera | $84 | $18,68744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 critical care medicine providers in Connecticut.
Other critical care medicine in Waterbury
- David HillWaterbury$193K
- Robert McDonaldWaterbury$13K
- Ferdinando UrbanoWaterbury$4K
- Elizabeth Mirabile-LevensWaterbury$3K
- Carl SherterWaterbury$1K
- Charis WipflerWaterbury$226
- Philip SimkovitzTrumbull$24K
- David KaufmanBridgeport$20K
- Roland El GhazalNew Haven$19K
- Akhil KhoslaNew Haven$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.